209 related articles for article (PubMed ID: 27607364)
1. Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).
Kim T; Pae AN
Expert Opin Ther Pat; 2016 Nov; 26(11):1325-1351. PubMed ID: 27607364
[TBL] [Abstract][Full Text] [Related]
2. Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).
Kim T; Pae AN
Expert Opin Ther Pat; 2016 Nov; 26(11):1353-1366. PubMed ID: 27599163
[TBL] [Abstract][Full Text] [Related]
3. Exploring Translocator Protein (TSPO) Medicinal Chemistry: An Approach for Targeting Radionuclides and Boron Atoms to Mitochondria.
Giordani A; Menziani MC; Moresco RM; Matarrese M; Paolino M; Saletti M; Giuliani G; Anzini M; Cappelli A
J Med Chem; 2021 Jul; 64(14):9649-9676. PubMed ID: 34254805
[TBL] [Abstract][Full Text] [Related]
4. Structural requirements to obtain highly potent and selective 18 kDa Translocator Protein (TSPO) Ligands.
Taliani S; Pugliesi I; Da Settimo F
Curr Top Med Chem; 2011; 11(7):860-86. PubMed ID: 21291396
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic actions of translocator protein (18 kDa) ligands in experimental models of psychiatric disorders and neurodegenerative diseases.
Arbo BD; Benetti F; Garcia-Segura LM; Ribeiro MF
J Steroid Biochem Mol Biol; 2015 Nov; 154():68-74. PubMed ID: 26200949
[TBL] [Abstract][Full Text] [Related]
6. The translocator protein (18kDa) and its role in neuropsychiatric disorders.
Barichello T; Simões LR; Collodel A; Giridharan VV; Dal-Pizzol F; Macedo D; Quevedo J
Neurosci Biobehav Rev; 2017 Dec; 83():183-199. PubMed ID: 29054730
[TBL] [Abstract][Full Text] [Related]
7. Guwiyang Wurra--'Fire Mouse': a global gene knockout model for TSPO/PBR drug development, loss-of-function and mechanisms of compensation studies.
Middleton RJ; Liu GJ; Banati RB
Biochem Soc Trans; 2015 Aug; 43(4):553-8. PubMed ID: 26551692
[TBL] [Abstract][Full Text] [Related]
8. Recent Developments in TSPO PET Imaging as A Biomarker of Neuroinflammation in Neurodegenerative Disorders.
Werry EL; Bright FM; Piguet O; Ittner LM; Halliday GM; Hodges JR; Kiernan MC; Loy CT; Kril JJ; Kassiou M
Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31261683
[TBL] [Abstract][Full Text] [Related]
9. Translocator Protein 18-kDa: A Promising Target to Treat Neuroinflammation- related Degenerative Diseases.
Tremolanti C; Germelli L; Barresi E; Da Pozzo E; Simorini F; Castellano S; Taliani S; Da Settimo F; Martini C; Costa B
Curr Med Chem; 2022 Aug; 29(28):4831-4861. PubMed ID: 35430971
[TBL] [Abstract][Full Text] [Related]
10. Translocator protein ligands as promising therapeutic tools for anxiety disorders.
Taliani S; Da Settimo F; Da Pozzo E; Chelli B; Martini C
Curr Med Chem; 2009; 16(26):3359-80. PubMed ID: 19548867
[TBL] [Abstract][Full Text] [Related]
11. Intracellular cholesterol changes induced by translocator protein (18 kDa) TSPO/PBR ligands.
Falchi AM; Battetta B; Sanna F; Piludu M; Sogos V; Serra M; Melis M; Putzolu M; Diaz G
Neuropharmacology; 2007 Aug; 53(2):318-29. PubMed ID: 17631921
[TBL] [Abstract][Full Text] [Related]
12. Benzodiazepine receptor ligands: a patent review (2006-2012).
Guerrini G; Ciciani G
Expert Opin Ther Pat; 2013 Jul; 23(7):843-66. PubMed ID: 23521498
[TBL] [Abstract][Full Text] [Related]
13. Targeting the 18-kDa translocator protein: recent perspectives for neuroprotection.
Da Pozzo E; Giacomelli C; Barresi E; Costa B; Taliani S; Passetti Fda S; Martini C
Biochem Soc Trans; 2015 Aug; 43(4):559-65. PubMed ID: 26551693
[TBL] [Abstract][Full Text] [Related]
14. The 18-kDa Translocator Protein as a CNS Drug Target: Finding Our Way Through the Neuroinflammation Fog.
Filiou MD; Banati RB; Graeber MB
CNS Neurol Disord Drug Targets; 2017; 16(9):990-999. PubMed ID: 28982340
[TBL] [Abstract][Full Text] [Related]
15. TSPO: An Evolutionarily Conserved Protein with Elusive Functions.
Bonsack F; Sukumari-Ramesh S
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29875327
[TBL] [Abstract][Full Text] [Related]
16. GABA
Crocetti L; Guerrini G
Expert Opin Ther Pat; 2020 Jun; 30(6):409-432. PubMed ID: 32200689
[No Abstract] [Full Text] [Related]
17. Evidence for complex binding profiles and species differences at the translocator protein (TSPO) (18 kDa).
Scarf AM; Luus C; Da Pozzo E; Selleri S; Guarino C; Martini C; Ittner LM; Kassiou M
Curr Mol Med; 2012 May; 12(4):488-93. PubMed ID: 22348617
[TBL] [Abstract][Full Text] [Related]
18. Development of new treatments for Alzheimer's disease based on the modulation of translocator protein (TSPO).
Arbo BD; Ribeiro MF; Garcia-Segura LM
Ageing Res Rev; 2019 Sep; 54():100943. PubMed ID: 31430564
[TBL] [Abstract][Full Text] [Related]
19. Translocator protein: pharmacology and steroidogenesis.
Midzak A; Zirkin B; Papadopoulos V
Biochem Soc Trans; 2015 Aug; 43(4):572-8. PubMed ID: 26551695
[TBL] [Abstract][Full Text] [Related]
20. TSPO in diverse CNS pathologies and psychiatric disease: A critical review and a way forward.
Guilarte TR
Pharmacol Ther; 2019 Feb; 194():44-58. PubMed ID: 30189290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
